Abstract: A woven mesh is provided for supporting tissue or an organ within a female patient's pelvis, and a method for using the same. The mesh includes a central portion having a width, a length, first and second ends, and first and second side edges, and first and second wing portions extending from the first and second ends of the central portion respectively. The first and second wing portions each have a width, a length, and first and second peripheral edges. The width of the wing portions are each greater than the width of the central portion, and when positioned within the female patient, the central portion is positioned below and supports the tissue or organ. A mesh is also provided having woven fibers with voids therebetween, and having a central portion and first and second ends. The average size of the voids at least in the central portion is at least 25–50 mm2, and when positioned within the patient, the central portion is positioned below and supports the tissue or organ.

Abstract: A woven mesh is provided for supporting tissue or an organ within a female patient's pelvis, and a method for using the same. The mesh includes a central portion having a width, a length, first and second ends, and first and second side edges, and first and second wing portions extending from the first and second ends of the central portion respectively. The first and second wing portions each have a width, a length, and first and second peripheral edges. The width of the wing portions are each greater than the width of the central portion, and when positioned within the female patient, the central portion is positioned below and supports the tissue or organ. A mesh is also provided having woven fibers with voids therebetween, and having a central portion and first and second ends. The average size of the voids at least in the central portion is at least 25-50 mm2, and when positioned within the patient, the central portion is positioned below and supports the tissue or organ.

Abstract: This invention relates (a) to a 540 kb YAC which encodes the necessary species-specific factor(s) and is able to substitute for human Chromosome 21 to reconstitute the Hu-IFN-gamma receptor-mediated induction of class I HLA antigens; (b) to the construction of a plasmid to integrate the selective marker for antibiotic G418 resistance into YACs and to delete some of the human DNA fragments from YACs in order to facilitate the manipulation of human genomic DNA in yeast artificial chromosome (YAC) clones; (c) to two fragmentation vectors, pSE1 and pSE2, which contain a neomycin resistance and URA3 gene, developed for targeting yeast artificial chromosomes (YACs) containing human genomic DNA; (d) to a chromosomal fragmentation procedure employed to produce a deletion set of yeast artificial chromosomes (YACs) from a parental YAC (GART D142H8) known to map to Chromosome 21q and to encode the human interferon-gamma receptor (Hu-IFN-gamma R) accessory factor gene as well as the phosphoribosylglycinamide formyltranis